PDCD1 and hepatocellular carcinoma: Early data for the clinical efficacy of ICIs in HCC were mostly from the CheckMate 040 and KEYNOTE-224 trials (both trials testing anti-PD-1 antibodies), which showed an objective response rate of 15–20% as a second-line setting (2, 3).